RT Journal Article
SR Electronic
T1 Elevated renin activity and change in sleep apnea with primary aldosteronism
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.01.24311390
DO 10.1101/2024.08.01.24311390
A1 Kidawara, Yonekazu
A1 Kadoya, Manabu
A1 Igeta, Masataka
A1 Kakutani-Hatayama, Miki
A1 Morimoto, Akiko
A1 Miyoshi, Akio
A1 Kanzaki, Akinori
A1 Konishi, Kosuke
A1 Daimon, Takashi
A1 Koyama, Hidenori
YR 2024
UL http://medrxiv.org/content/early/2024/08/03/2024.08.01.24311390.abstract
AB Background The prevalence of obstructive sleep apnea (OSA) is higher in patients with primary aldosteronism (PA), while elevated renin activity after treatment is associated with a lower risk of cardiovascular events. However, the association of PA with degree of OSA remains unclear and it is not known whether elevated renin activity in PA patients is associated with change in apnea condition.Methods Cross-sectional relationships between PA (n=176) and degree of OSA classified by apnea-hypopnea index (AHI) with use of an apnomonitor were investigated, with the results compared with those obtained with non-PA patients (n=418). Additionally, the effects of elevated renin activity on change in AHI were prospectively examined in 45 patients with PA.Results Patients with PA were found to be significantly associated with severe OSA even after adjustment for other clinical risk factors (odds ratio 2.08, 95% confidence interval 1.09-3.95, p = 0.025) as compared to those without PA. Furthermore, the logarithm of the renin activity after treatment and change in AHI before and after treatment were significantly negatively correlated, with Pearson’s correlation coefficient (r = -0.364, p = 0.014).Conclusions Severe OSA is more commonly seen in PA patients with hypertension as compared to patients without PA, and elevated renin activity may contribute to improvement of sleep apnea in patients with PA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJSPS KAKENHI grants (24K19043 to Y. Kidawara, 20K18944 to A. Mrimoto) and Hyogo Medical University (Hyogo Innovative Challenge to H. Koyama) were received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional ethical committee of Hyogo Medical University (approval No. 2351)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated during and/or analyzed for the current study are not publicly available, though can be provided by the corresponding author upon reasonable request.